Allogene Therapeutics - ALLO STOCK NEWS

Allogene Therapeutics (NASDAQ: ALLO) has expanded its strategic partnership with Foresight Diagnostics to develop minimal residual disease (MRD) assay as a companion diagnostic for cemacabtagene ansegedleucel (cema-cel) treatment in large B-cell lymphoma (LBCL) patients across Europe, UK, Canada, and Australia.

The collaboration focuses on using Foresight's CLARITY™ assay to identify MRD-positive patients in the pivotal ALPHA3 trial, where cema-cel is being studied as a first-line treatment. The assay will help identify high-risk patients who achieve remission but remain MRD positive, offering them a one-time consolidation dose of cema-cel to prevent disease recurrence.

Under the agreement, Allogene will invest $37.3 million for MRD assay development, milestone payments for regulatory submissions, and clinical sample testing. Both companies will work towards obtaining regulatory approvals for their respective products.

Allogene Therapeutics published Phase 1 ALPHA/ALPHA2 trial results for cemacabtagene ansegedleucel (cema-cel) in treating relapsed/refractory large B-cell lymphoma. The study demonstrated significant efficacy with 58% overall response rate and 42% complete response rate across all patients, improving to 67% and 58% respectively with the pivotal study regimen.

Key highlights include a median duration of response of 23.1 months among complete responders, with median overall survival not reached. The treatment showed a manageable safety profile with no graft-versus-host disease, neurotoxicity syndrome, or high-grade cytokine release syndrome. Notably, the median time to treatment was just two days from enrollment.

The study revealed 100% complete response rates in patients with low disease burden, supporting the ongoing ALPHA3 trial which evaluates cema-cel as a first-line consolidation therapy. This represents the largest dataset of LBCL patients treated with an allogeneic CAR T product, with minimum two-year follow-up.

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation is scheduled for Wednesday, February 12, at 12:20 PM PT/3:20 PM ET. Webcasts will be available on the company's website under the Investors tab, with replays accessible for approximately 30 days after the event.

Allogene Therapeutics (Nasdaq: ALLO) has announced the promotion of Benjamin M. Beneski to Senior Vice President and Chief Technical Officer (CTO). He succeeds Tim Moore, who will step down at the end of February after two years with the company. Beneski, who joined Allogene in 2019, will oversee technical operations and advance the company's allogeneic cell therapy programs.

Beneski's experience includes leading the design and construction of Cell Forge 1, the company's manufacturing facility, and serving as Vice President of Manufacturing and Vice President of Product Development and Manufacturing. His career spans over 20 years in biologics manufacturing, with previous roles at Vir Biotechnology and Amgen.

Allogene Therapeutics (ALLO) has received FDA clearance for its Investigational New Drug (IND) application for ALLO-329, a dual-targeted CD19/CD70 allogeneic CAR T product designed for autoimmune diseases. The company plans to initiate the Phase 1 RESOLUTION basket trial in mid-2025, targeting systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.

The trial will utilize Allogene's proprietary Dagger® technology to enhance CAR T cell expansion and prevent rejection, featuring two lymphodepletion arms: one using cyclophosphamide alone and another without lymphodepletion. ALLO-329's dual-targeting design against CD19+ B-cells and CD70+ activated T-cells aims to address immune dysregulation in autoimmune diseases. The company's manufacturing capacity can potentially produce up to 60,000 doses annually.

Allogene Therapeutics (ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease treatment, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. David Chang, M.D., Ph.D., the company's President, CEO, and Co-Founder, will deliver a presentation at the Westin St. Francis in San Francisco on Wednesday, January 15, 2025, at 3:00 PM PT/ 6:00 PM ET.

A live audio webcast will be available on Allogene's website under the Investors tab, with a replay accessible for approximately 30 days following the presentation.

Allogene Therapeutics (ALLO) announced the passing of founding board member David Bonderman at age 82. Bonderman, who served as Lead Independent Director since the company's founding in 2018, was instrumental in advancing CAR T-cell therapy development. He was an early supporter of Kite Pharma and later helped establish and guide Allogene's evolution in developing allogeneic CAR T products for cancer and autoimmune disease treatment. His role as a champion of innovation and trusted mentor made significant contributions to the company's development in pioneering AlloCAR T™ products.

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company focused on allogeneic CAR T products for cancer and autoimmune disease, has announced its participation in upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference on November 20, 2024, at 11:30AM GMT, the Citizens JMP Hematology and Oncology Summit on December 2, 2024, and the 36th Annual Piper Sandler Healthcare Conference on December 3, 2024. Webcasts will be available on the company's website for approximately 30 days after the events.

Allogene Therapeutics presented preclinical data for ALLO-329, a novel dual CAR T cell therapy targeting both CD19+ B-cells and CD70+ activated T cells for autoimmune diseases. The therapy demonstrated effective depletion of target cells and reduction in IgG and IgM without requiring lymphodepletion in preclinical models. Using proprietary Dagger® technology, ALLO-329 showed resistance to rejection and enhanced persistence. The company plans to submit an IND application in Q1 2025, with proof-of-concept expected by year-end 2025.